Cannabis Report
Home > Boards > US Listed > Biotechs >

Anavex Life Sciences Corp (AVXL)

Add AVXL Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, Steady_T, blanka, neiu, TomP1, Rubyred77
Search This Board: 
Last Post: 8/15/2018 2:49:07 PM - Followers: 715 - Board type: Free - Posts Today: 53

Anavex Life Sciences Corp (AVXL)

Company website:
Company Address:
51 West 52nd Street, 7th floor
New York, NY
10019 USA

CIK:  0001314052

Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer.  The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.

Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease.  ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors.  Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others.  The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial.  ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.

The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.

Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL


Patent Info:

Clinical Trials:
Recent News:
Company News Releases:
Share Structure:  See SEC filings
Investor Relations:

Marketing Details:


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:

Cannabis Report
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVXL News: Quarterly Report (10-q) 08/09/2018 04:48:27 PM
AVXL News: Anavex Life Sciences Reports Fiscal Third Quarter 2018 Financial Results 08/09/2018 07:00:00 AM
AVXL News: Anavex Life Sciences to Announce Fiscal Third Quarter 2018 Financial Results on Thursday, August 9, 2018 08/07/2018 07:00:00 AM
AVXL News: Penny Stocks With Massive Upside Potential and Massive Downside Risk 07/30/2018 04:29:05 PM
AVXL News: Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers in Alzheimer’s Disease Patients Treated wi... 07/25/2018 09:00:00 AM
PlusOneCoin Top Posts
#162831   Alzheimer's, Parkinsons and Retts are only the beginning. dia76ca 08/14/18 01:27:13 PM
#162428   brichnyc what is that inflection point where the nidan7500 08/10/18 04:11:00 PM
#162469   dramnesia1, it seems you’re spending some time this polarbear77 08/10/18 09:16:09 PM
#162698  Sticky Note Hampel SPEAKS!.... (update2 ) XenaLives 08/13/18 09:27:13 AM
#160507  Sticky Note here are a couple of those 32 from cninc 07/30/18 12:01:12 AM
#141363  Sticky Note DD re: discussion of genome sequencing database: This is Biostockclub 02/16/18 04:07:56 PM
#135567  Sticky Note Good lessons learned from AVXL investment in 2017. Rising_Sun 12/29/17 02:53:39 AM
#129044  Sticky Note People seem to always lose track of the dadofmarcmax 11/06/17 10:58:33 AM
#162927   Yes I can imagine Nile or Amazon river sage4 08/15/18 02:49:07 PM
#162926   Biogen getting dumped today down over $5.00! bennyboy1 08/15/18 02:39:02 PM
#162925   Intraday steps of support and resistance 123tom 08/15/18 02:12:44 PM
#162924   By EOD we might again see $AVXL return Investor2014 08/15/18 02:06:28 PM
#162923   Today's price also market influenced. XenaLives 08/15/18 01:44:18 PM
#162922   What I found on Sig-1R mentioning exosomes. XenaLives 08/15/18 01:41:18 PM
#162921   My point is even with toxicity you are XenaLives 08/15/18 01:35:32 PM
#162920   If you read the whole thing I stated Buckboard 08/15/18 01:22:54 PM
#162919   Today's price action 123tom 08/15/18 12:56:27 PM
#162918   This is the first study I've seen showing roygbiv 08/15/18 12:55:08 PM
#162917   Metal toxicity from implants causing serious neurological issues: XenaLives 08/15/18 12:21:49 PM
#162916   I quoted the hypothesis I thought was unproven XenaLives 08/15/18 12:09:08 PM
#162915   Most companies are very protective of their data, TempePhil 08/15/18 12:08:39 PM
#162914   N=10 sounds about a third as convincing as Investor2014 08/15/18 11:57:36 AM
#162913   No, this paper was published from a study roygbiv 08/15/18 11:49:19 AM
#162912   Isn't this paper based on an unproven hypothesis? XenaLives 08/15/18 11:39:45 AM
#162911   Alzheimer’s disease pathology propagation by exosomes containing toxic roygbiv 08/15/18 11:33:08 AM
#162910   They publish everything they can that is appropriate frrol 08/15/18 11:27:56 AM
#162909   RE: Pre-clinical Data MycroftHolmes 08/15/18 11:20:06 AM
#162908   The whole market is in sell off mode Investor2014 08/15/18 11:19:17 AM
#162907   Trades >=500 - Mostly HFT and no volume: XenaLives 08/15/18 11:14:16 AM
#162906   Then it is clearly information that they don't XenaLives 08/15/18 11:11:23 AM
#162905   Sounds like another plaque attack drug... XenaLives 08/15/18 11:10:23 AM
#162904   It's an SBIR phase 2 grant so they Doc328 08/15/18 11:01:22 AM
#162903   I have done both and have not received Jonjones325 08/15/18 10:49:41 AM
#162902   NIH grants PTIE millions for AD today. Is biotechnician 08/15/18 10:43:25 AM
#162901   why don't you call them as you are rayovacAAA 08/15/18 10:31:48 AM
#162900   Update from the Engel family. kevli33 08/15/18 09:59:24 AM
#162899   Sad story. There is hope Mr Engel. kevli33 08/15/18 09:46:23 AM
#162898   Disputing that as the cause would be F1ash 08/15/18 09:45:37 AM
#162897   That argument is a fail because 2-73 has XenaLives 08/15/18 09:37:01 AM
#162896   I think the dose/toxicity formula Flash posted a Buckboard 08/15/18 09:30:46 AM
#162895   The company releases everything they can from pre-clinical frrol 08/15/18 09:27:50 AM
#162894   For anyone questioning why choose Australia. Not kevli33 08/15/18 09:24:54 AM
#162893   From our friends at STAT News. Neurotrope is Investor2014 08/15/18 09:23:17 AM
#162892   Thanks TTT.. McMagyar 08/15/18 08:58:58 AM
#162891   TTT---great find---Thanks for posting !!!!! plexrec 08/15/18 08:51:12 AM
#162890   Not sure any of the posters you've mentioned ExtremelyBullishZig 08/15/18 08:25:52 AM
#162889   Rett design is in trouble - few knowledgeable Amatuer17 08/15/18 08:24:55 AM
#162881   It is worth repeating, a primary reason for xodcode 08/15/18 07:02:57 AM
#162880   JJ, why don't you call them as you powerwalker 08/15/18 06:37:48 AM
#162879   Nice to see Anavex includes expected reduction of insomnia. Investor2014 08/15/18 05:09:11 AM
#162878   What else could the hold up be? F1ash 08/15/18 03:33:20 AM
#162877   As the alternative to the slow climb through Talon38 08/15/18 01:31:16 AM
#162876   Has anyone spoken to the new IR people Jonjones325 08/15/18 12:52:24 AM
#162875   TTT, You have become quite the scout for all rocalinda 08/15/18 12:15:42 AM
#162873   Anavex's PDD trial recruitment video. En español: TTTav66 08/14/18 10:49:38 PM
#162872   How do I forsee the revenue stream? XenaLives 08/14/18 09:59:09 PM
#162871   Love it, and your not so often posts. Jimmy6969 08/14/18 09:48:33 PM
#162870   OK Xena, I'll bite.... how do you foresee jbcan07 08/14/18 09:17:03 PM